Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether multiple doses of Efavirenz has an effect
on the QTc interval (corrected by Fridericia) in CYP2B6 *1/*6 and *6/*6 healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Efavirenz Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination